Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. These updates
provide information on experimental drugs and at times give an
insight into the commercial potential of the candidate once it is
successfully developed and commercialized.
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
ARATANA THERAP (PETX): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
VANDA PHARMACT (VNDA): Free Stock Analysis
To read this article on Zacks.com click here.
Earlier this week,
Aratana Therapeutics, Inc.
) provided an update on its pipeline. The company stated in its
press release that it has progressed well with its candidates
during 2013, achieving previously stated milestones.
In Nov 2013, Aratana announced positive top-line results from its
pivotal dose-ranging study on AT-001. The candidate is being
developed for the treatment of pain in dogs suffering from
osteoarthritis. Results revealed that significant improvement in
pain assessment scores were observed in dogs receiving AT-001
compared to those on placebo.
Aratana now plans to advance AT-001 into a pivotal field
effectiveness study in 2014. Positive results from the pivotal
field effectiveness study will allow the company to seek approval
of the candidate. Aratana intends to commercialize AT-001 in
The company further stated that it initiated a pivotal field
effectiveness study on AT-002, another important candidate at
Aratana. AT-002 is being developed for the treatment of dogs
suffering from inappetence. Aratana intends to start enrolling
dogs for the study in Jan 2014. An anticipated 150 client-owned
dogs are expected to be enrolled for the study. Top-line results
from the study are expected in the first half of 2015 with
approval expected in 2016.
Moreover, Aratana intends to initiate a pilot field study on
AT-003 in client-owned dogs in 2014. The candidate will be
studied for assessing pain management following orthopedic
surgery in client-owned dogs.
We are encouraged by the company's progress with its pipeline so
far. We expect investor focus to remain on Aratana's pipeline
Aratana, a biopharmaceutical company focusing exclusively on
pets, currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the biopharmaceutical sector include
Vanda Pharmaceuticals Inc.
). All the stocks carry a Zacks Rank #1 (Strong Buy).